Survodutide meets CV safety bar in Phase 3 obesity trial

Boehringer Ingelheim said on November 9, 2026 that survodutide (BI 456906), an investigational once-weekly glucagon/GLP-1 dual agonist licensed from Zealand Pharma, met its primary cardiovascular safety goal in the Phase 3 SYNCHRONIZE-CVOT trial. The result was noninferiority versus placebo, not superiority. The findings were presented at the American Heart Association Scientific Sessions 2026 in Chicago and published the same day in The Lancet.

Boehringer’s release described the drug as “the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile.” That is the company’s characterization, not an independent ranking. The company also said survodutide “has not been approved for use, and its efficacy and safety have not been established.”

The trial

SYNCHRONIZE-CVOT (NCT06077864) is a Phase 3, double-blind, placebo-controlled, event-driven cardiovascular safety study. ClinicalTrials.gov lists it as completed, with actual enrollment of 5,530, matching the figure in Boehringer’s and Zealand’s releases. Participants were adults with overweight or obesity plus established cardiovascular disease, chronic kidney disease, and/or at least two weight-related complications or risk factors for cardiovascular disease. The enrolled population included people with type 2 diabetes. Participants received a weekly injection of survodutide at a “3.6 mg” or “6.0 mg” dose, or placebo.

The primary endpoint was the time to the first adjudicated component of a 5-point MACE composite: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, ischemia-related coronary revascularization, or a heart failure event, tested for noninferiority.

Heart outcomes: noninferior, not superior

Boehringer said the trial met its primary endpoint under both the treatment-regimen estimand and a supplementary secondary estimand. The hazard ratio it published is the treatment-regimen figure, which estimates the effect regardless of whether participants stayed on treatment, discontinued, or started other therapies.

On that treatment-regimen analysis, the primary 5-point MACE hazard ratio was 0.89 (95% CI, 0.67 to 1.18), with p under 0.0001 for noninferiority. The company said survodutide “did not increase the risk of major adverse cardiovascular events” compared with placebo. The confidence interval includes 1, so this is not a demonstration that survodutide reduced those events. AJMC reported the same primary figures.

A key secondary 3-point MACE composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke also met noninferiority on the treatment-regimen estimand: hazard ratio 0.84 (95% CI, 0.60 to 1.18), p under 0.0001 for noninferiority.

The company said the primary endpoint was met under the supplementary secondary estimand as well, but the release did not print a separate primary hazard ratio for that analysis.

Weight and other measures at 72 weeks

Cardiometabolic secondaries were reported at 72 weeks on the supplementary secondary estimand, which Boehringer defined as “the effect expected with continued treatment, assuming no intercurrent events.” The company said that analysis is conceptually similar to the efficacy estimand in the other SYNCHRONIZE studies.

On that estimand, Boehringer reported body-weight reductions of up to 13.7% with survodutide versus 2.0% with placebo; systolic blood pressure reductions of up to 6.68 mm Hg versus 1.76 mm Hg (P= 0.0001); and waist-circumference reductions of up to 11.96 cm versus 2.74 cm. The “up to” figures correspond to the highest reported arm in the company release, which did not break out the “3.6 mg” dose separately. The company also said high-sensitivity C-reactive protein (hs-CRP) and triglycerides fell versus placebo, without publishing numeric changes in the release.

Safety

The most common adverse events were gastrointestinal, and Boehringer said those events were mostly mild to moderate, with nausea, vomiting, diarrhea, and constipation the most common. Treatment discontinuation because of gastrointestinal adverse events was 19.3% among people who received the “3.6 mg” dose and 20.8% among those who received the “6.0 mg” dose, compared with 1.9% on placebo.

What Boehringer plans to file

Boehringer said that, based on the SYNCHRONIZE program, it is “moving forward with preparations for regulatory submissions in obesity.” The official release does not name a year. Fierce Biotech, in an interview with Neerja Balachander, who oversees clinical development medical affairs for cardio-renal-metabolism at Boehringer, reported that the company aims for a 2027 submission and that Balachander said the aim is to submit a weight-loss application “at some time in the next year.” She also said, “If we could, we would do it as soon as possible,” and that it is “a conversation with the regulators.”

The same day’s American Heart Association meeting also included other obesity-drug readouts, including Eli Lilly’s ATTAIN-OSA results for Foundayo (report).

What is not known

• The Lancet tables. Boehringer cited a simultaneous Lancet paper (doi 10.1016/S0140-6736(26)02140-9). The full text and abstract were not retrievable at the time this story was written, so the hazard ratios printed here are those in Boehringer’s and Zealand’s releases, which AJMC also reported. A meeting write-up in Healio listed a different point estimate for the primary 5-point analysis than the company release; until the journal tables can be checked, that figure is not used here.
• The unpublished estimand. Boehringer said the primary endpoint was met under both estimands but published only the treatment-regimen hazard ratios for 5-point and 3-point MACE.
• Per-dose cardiometabolic splits and biomarker deltas. The company release gives week-72 weight, blood pressure, and waist changes as “up to” figures and does not quantify the hs-CRP or triglyceride changes.
• Filing timing. A 2027 submission is Fierce Biotech’s report of an interview, not a date in the company release. Survodutide remains investigational.
• Superiority and long-term benefit. The trial was designed to test cardiovascular safety by noninferiority. It does not establish that survodutide prevents heart attacks, strokes, or heart failure, and it does not show how results would look beyond the observed follow-up.